Showing 18 results for Injury
The Surviving Blood Loss (SBL) program is developing novel strategies to radically extend the time injured warfighters can survive critical blood loss on the battlefield before initiation of fluid and blood resuscitation. Achieving this goal will allow increased time—as much as hours or days—for evacuation, triage, and initiation of supportive therapies.
Uncontrolled blood loss is the leading cause of death for warfighters on the battlefield, according to the U.S. Army Institute of Surgical Research. The vast majority of such fatalities are from wounds that are not accessible by combat medics for traditional treatments, like direct compression. For example, in the case of internal injuries to the abdominal cavity, medics can neither visualize the damage nor access it to provide treatment. As a result, rapid and uncontrolled blood loss often leads to death before transport from the battlefield to a surgical setting can occur.
Military service members and veterans face serious occupational trauma; one
element in particular relates to the significantly increased risk of acute
and chronic neuropsychiatric conditions. Neuropsychiatric conditions in the
military are particularly impactful because options for treating them are
limited. No therapy currently exists that can deliver rapid relief of
neuropsychiatric symptoms and is reasonable for use in a broad spectrum of
conditions. Neuropsychiatric conditions are complex, and presentation is
highly subject to significant inter-individual variability. Focused Pharma
aims to develop new drugs that target specific neurotransmitter receptor
signaling modes to deliver near immediate relief that is generalizable
across indications and individuals.